A three-drug combination targeting aggressive advanced breast cancer could potentially double the amount of time patients live without the disease progressing, a trial has found. Researchers hailed the “huge breakthrough” as potentially “transformative” for those with a common form of breast cancer. A mutation in the gene known as PIK3CA causes cells to divide and replicate uncontrollably, leading to the development of PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study, known as INAVO120 and published in the The New…